The newborn human infant is especially susceptible to bacterial infections because of immature host defenses. One of the most consistent defects in the neonate's host defense system is a marked abnormality in polymorphonuclear leukocyte chemotaxis. Unfortunately, very little is known about the pathogenesis of this developmental defect in cell movement. In studies carried out during the first two years of this grant, we have shown that the PMNs from neonates fail to form polymerized, or F actin, from gel actin following stimulation with chemoattractant; a process which is essential in providing the contractile forces required for cell movement. Additional experiments indicate that the PMNs from neonates fail to undergo critical changes in membrane potential following chemotactic factor stimulation and develop lower concentrations of intracellular free calcium. The early cyclic adenosine 3'5' monophosphate (cAMP) response to chemotactic factor stimulation is also blunted in the PMNs from neonates. These results suggest that an abnormality in signal transduction may result in the developmental abnormality in cell motility observed in the human neonate. Based on these rather exciting preliminary results, we wish to attempt to define the exact mechanism(s) of the defect and attempt to correct the abnormality. Specifically, we will 1) determine if the rigid cell membrane of the PMNs from neonates is preventing lateral mobility of receptors and blunting or blocking signal transduction; 2) attempt to define the reasons for, and significance of, the lack of changes in membrane potential and the smaller increases in intracellular in free intracellular calcium in the neonatal PMN; and 3) attempt to develop pharmacologic regimens for correcting the chemotactic responsiveness of PMNs from neonates.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI019094-04
Application #
3128520
Study Section
Bacteriology and Mycology Subcommittee 1 (BM)
Project Start
1982-09-01
Project End
1988-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Utah
Department
Type
Schools of Medicine
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Hill, H R; Augustine, N H; Jaffe, H S (1991) Human recombinant interferon gamma enhances neonatal polymorphonuclear leukocyte activation and movement, and increases free intracellular calcium. J Exp Med 173:767-70
Yang, K D; Hill, H R (1991) Neutrophil function disorders: pathophysiology, prevention, and therapy. J Pediatr 119:343-54
Hill, H R (1991) The role of intravenous immunoglobulin in the treatment and prevention of neonatal bacterial infection. Semin Perinatol 15:41-6
Jeppson, J D; Jaffe, H S; Hill, H R (1991) Use of recombinant human interferon gamma to enhance neutrophil chemotactic responses in Job syndrome of hyperimmunoglobulinemia E and recurrent infections. J Pediatr 118:383-7
Salyer, J L; Bohnsack, J F; Knape, W A et al. (1990) Mechanisms of tumor necrosis factor-alpha alteration of PMN adhesion and migration. Am J Pathol 136:831-41
Yang, K D; Bohnsack, J F; Hawley, M M et al. (1990) Effect of fibronectin on IgA-mediated uptake of type III group B streptococci by phagocytes. J Infect Dis 161:236-41
Bohnsack, J F; Hawley, M M; Pritchard, D G et al. (1989) An IgA monoclonal antibody directed against type III antigen on group B streptococci acts as an opsonin. J Immunol 143:3338-42
Hill, H R; Shigeoka, A O; Gonzales, L A et al. (1989) Intravenous immune globulin use in newborns. J Allergy Clin Immunol 84:617-23;discussion 623-4
Newton, J A; Ashwood, E R; Yang, K D et al. (1989) Effect of pentoxifylline on developmental changes in neutrophil cell surface mobility and membrane fluidity. J Cell Physiol 140:427-31
Yang, K D; Bathras, J M; Shigeoka, A O et al. (1989) Mechanisms of bacterial opsonization by immune globulin intravenous: correlation of complement consumption with opsonic activity and protective efficacy. J Infect Dis 159:701-7

Showing the most recent 10 out of 30 publications